Adverse cardiovascular outcomes between insulin-treated and non-insulin treated diabetic patients after percutaneous coronary intervention: a systematic review and meta-analysis

Cardiovascular Diabetology

Meng-Hua Chen¹  Nuo Li¹  Pravesh Kumar Bundhun¹ 

[1] Institute of Cardiovascular Diseases, The First Affiliated Hospital of Guangxi Medical University, Nanning 530027, Guangxi, People’s Republic of China

关键词: Percutaneous coronary intervention;    Type 2 diabetes mellitus;    Cardiovascular outcomes;   

Others  :  1228710
DOI  :  10.1186/s12933-015-0300-6

 received in 2015-09-08, accepted in 2015-09-30,  发布年份 2015

【 摘 要 】

Background

Type 2 diabetes mellitus (DM) patients have worse adverse cardiovascular outcomes after Percutaneous Coronary Intervention (PCI). However, the adverse cardiovascular outcomes between insulin-treated and non-insulin treated DM patients have been a subject of debate. We sought to compare the short-term (<1 year) and long-term (≥1 year) cardiovascular outcomes between insulin-treated and non-insulin treated DM patients after PCI.

Methods

Medline and Embase databases were searched for studies by typing ‘diabetes and percutaneous coronary intervention/PCI’ or ‘insulin-treated and non-insulin treated diabetes mellitus and PCI’. Endpoints included adverse cardiovascular outcomes reported in these DM patients during the corresponding follow-up periods. Odd Ratio (OR) with 95 % confidence interval (CI) was used to express the pooled effect on discontinuous variables and the pooled analyses were performed with RevMan 5.3.

Results

21 studies have been included in this meta-analysis consisting of a total of 21,759 diabetic patients (6250 insulin-treated and 15,509 non-insulin treated DM patients). Short term mortality, myocardial infarction, target lesion revascularization, major adverse cardiac effects and, stent thrombosis were significantly higher in insulin-treated diabetic patients (OR 1.69, 95 % CI 1.40–2.04, p < 0.00001), (OR 1.40, 95 % CI 1.16–1.70, p = 0.0005), (OR 1.37, 95 % CI 1.06–1.76, p = 0.02), (OR 1.46, 95 % CI 1.22–1.76, p < 0.0001) and (OR 1.66, 95 % CI 1.16–2.38, p = 0.005) respectively. Long-term cardiovascular outcomes were also significantly higher in insulin-treated DM patients.

Conclusion

Insulin treatment in these DM patients was associated with a significantly higher short and long-term adverse cardiovascular outcomes after PCI compared to those DM patients not treated by insulin therapy.

【 授权许可】

   
2015 Bundhun et al.

【 图 表 】

Fig.1.

Fig.2.

Fig.3.

Fig.4.

【 参考文献 】

• [1]Tada T, Kimura T, Morimoto T, Ono K, Furukawa Y, Nakagawa Y et al.. Comparison of 3 year clinical outcomes after sirolimus eluting stent implantation among insulin-treateddiabetic, non-insulin-treated diabetic, and non-diabetic patients from j-Cypher registry. Am J Cardiol. 2011; 107(8):1155-1162.
• [2]Akin I, Bufe A, Eckardt L, Reinecke H, Senges J, Richardt G et al.. Comparison of outcomes in patients with insulin-dependent versus non-insulin dependent diabetes mellitusreceiving drug-eluting stents (from the first phase of the prospective multicenter German DES.DE registry). Am J Cardiol. 2010; 106(9):1201-1207.
• [3]Kirtane AJ, Ellis SG, Dawkins KD, Colombo A, Grube E, Popma JJ et al.. Paclitaxel-eluting coronary stents in patients with diabetes mellitus: pooled analysis from 5 randomized trials. J Am Coll Cardiol. 2008; 51(7):708-715.
• [4]Higgins JPT, Altman DG. Assessing risk of bias in included studies. In: Higgins JPT, Green S, eds. Cochrane handbook for systematic reviews of interventions. Wiley, 2008:187-241.
• [5]Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP et al.. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcareinterventions: explanation and elaboration. BMJ. 2009; 339:b2700.
• [6]Elezi S, Kastrati A, Pache J, Wehinger A, Hadamitzky M, Dirschinger J et al.. Diabetes mellitus and the clinical and angiographic outcome after coronary stent placement. J Am Coll Cardiol. 1998; 32(7):1866-1873.
• [7]Mathew V, Gersh BJ, Williams BA, Laskey WK, Willerson JT, Tilbury RT et al.. Outcomes in patients with diabetes mellitus undergoing percutaneous coronary intervention in the current era: a report from the Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) trial. Circulation. 2004; 109(4):476-480.
• [8]Dangas GD, Farkouh ME, Sleeper LA, Yang M, Schoos MM, Macaya C et al.. Long-term outcome of PCI versus CABG in insulin and non-insulin-treated diabetic patients: results from the FREEDOM trial. J Am Coll Cardiol. 2014; 64(12):1189-1197.
• [9]Muniyappa R, Montagnani M, Koh KK, Quon MJ. Cardiovascular actions of insulin. Endocr Rev. 2007; 28:463-491.
• [10]Potenza MA, Addabbo F, Montagnani M. Vascular actions of insulin with implications for endothelial dysfunction. Am J Physiol Endocrinol Metab. 2009; 297:E568-E577.
• [11]Wang MY, Yu X, Lee Y et al.. Iatrogenic hyperinsulinemia in type 1 diabetes: its effect on atherogenic risk markers. J Diabetes Compl. 2013; 27:70-74.
• [12]Unger RH, Orci L. Paracrinology of islets and the paracrinopathy of diabetes. Proc Natl Acad Sci USA. 2010; 107:16009-16012.
• [13]Wang M-Y, Yu X, Lee L et al.. Iatrogenic hyperinsulinemia in type 1 diabetes: its effect on atherogenic risk markers. J Diabetes Complications. 2009; 27:70-74.
• [14]Moreno PR, Murcia AM, Palacios I, Leon MN, Bernardi VH, Fuster V. Coronary composition and macrophage infiltation in atherectomy specimens from patients with diabetes mellitus. Circulation. 2002; 102:2180-2184.
• [15]Kumar R, Lee TT, Jeremias A, Ruisi CP, Sylvia B, Magallon J et al.. Comparison of outcomes using sirolimus-eluting stenting in diabetic versus nondiabetic patients with comparison of insulin versus non-insulin therapy in the diabetic patients. Am J Cardiol. 2007; 100(8):1187-1191.
• [16]Kirtane AJ, Patel R, O’Shaughnessy C, Overlie P, McLaurin B, Solomon S et al.. Clinical and angiographic outcomes in diabetics from the ENDEAVOR IV trial: randomized comparison of zotarolimus- and paclitaxel-eluting stents in patients with coronary artery disease. JACC Cardiovasc Interv. 2009; 2(10):967-976.
• [17]Claessen BE, Dangas GD, Godino C, Lee SW, Obunai K, Carlino M et al.. Long-term clinical outcomes of percutaneous coronary intervention for chronic total occlusions in patients withversus without diabetes mellitus. Am J Cardiol. 2011; 108(7):924-931.
• [18]Moussa I, Leon MB, Baim DS, O’Neill WW, Popma JJ, Buchbinder M et al.. Impact of sirolimus-eluting stents on outcome in diabetic patients: a SIRIUS (SIRolImUS-coated Bx Velocity balloon-expandable stent in the treatment of patients with de novo coronary artery lesions) substudy. Circulation. 2004; 109(19):2273-2278.
• [19]Daemen J, Garcia-Garcia HM, Kukreja N, Imani F, de Jaegere PP, Sianos G et al.. The long-term value of sirolimus- and paclitaxel-eluting stents over bare metal stents in patients with diabetes mellitus. Eur Heart J. 2007; 28:26-32.
• [20]Trifunovic D et al.. Acute insulin resistance in ST-segment elevation myocardial infarction in non-diabetic patients is associated with incomplete myocardial reperfusion and impaired coronary microcirculatory function. Cardiovasc Diabetol. 2014; 13:73. BioMed Central Full Text
• [21]Iguchi T et al.. Insulin resistance is associated with coronary plaque vulnerability: insight from optical coherence tomography analysis. Eur Heart J Cardiovasc Imaging. 2014; 15(3):284-291.
• [22]Lopez-de-Andres A et al.. National trends in utilization and outcomes of coronary revascularization procedures among people with and without type 2 diabetes in Spain (2001–2011). Cardiovasc Diabetol. 2014; 13:3. BioMed Central Full Text
• [23]Kuramitsu S et al.. Impact of post-challenge hyperglycemia on clinical outcomes in Japanese patients with stable angina undergoing percutaneous coronary intervention. Cardiovasc Diabetol. 2013; 12:74. BioMed Central Full Text
• [24]Ong AT, Aoki J, van Mieghem CA, Rodriguez Granillo GA, Valgimigli M, Tsuchida K et al.. Comparison of short- (1 month) and long- (12 months) term outcomes of sirolimus- versus paclitaxel-eluting stents in 293 consecutive patients with diabetes mellitus (from the RESEARCH and T-SEARCH registries). Am J Cardiol. 2005; 96:358-362.
• [25]Berenguer A, Mainar V, Bordes P, Valencia J, Gomez S. Efficacy of sirolimus-eluting stents in diabetics with complex coronary lesions. Rev Esp Cardiol. 2006; 59:117-124.
• [26]De Luca G, Dirksen MT, Spaulding C, Kelbæk H, Schalij M, Thuesen L et al.. Meta-analysis comparing efficacy and safety of first generation drug-eluting stents to bare-metal stents in patients with diabetes mellitus undergoing primary percutaneous coronary intervention. Am J Cardiol. 2013; 111(9):1295-1304.
• [27]Liu Y, Gao L, Song Y, Chen L, Xue Q, Tian J, Wang Y, Chen Y. Efficacy and safety of limus-eluting versus paclitaxel-eluting coronary artery stents in patients with diabetes mellitus: a meta-analysis. Int J Cardiol. 2015; 184:680-691.
• [28]Bangalore S, Kumar S, Fusaro M, Amoroso N, Kirtane AJ, Byrne RA et al.. Outcomes with various drug eluting or bare metal stents in patients with diabetes mellitus: mixed treatment comparison analysis of 22,844 patient years of follow-up from randomised trials. BMJ. 2012; 345:e5170.
• [29]Verma S, Farkouh ME, Yanagawa B, Fitchett DH, Ahsan MR, Ruel M et al.. Comparison of coronary artery bypass surgery and percutaneous coronary intervention in patients with diabetes: a meta-analysis of randomised controlled trials. Lancet Diabetes Endocrinol. 2013; 1(4):317-328.
• [30]Abizaid A, Kornowski R, Mintz GS, Hong MK, Abizaid AS, Mehran R et al.. The influence of diabetes mellitus on acute and late clinical outcomes following coronary stent implantation. J Am Coll Cardiol. 1998; 32:584-589.
• [31]Antoniucci D, Valenti R, Migliorini A, Parodi G, Moschi G, Memisha G et al.. Impact of insulin requiring diabetes mellitus on effectiveness of reperfusion and outcome of patients undergoing primary percutaneous coronary intervention for acute myocardial infarction. Am J Cardiol. 2004; 93(9):1170-1172.
• [32]Hermiller JB, Raizner A, Cannon L, Gurbel PA, Kutcher MA, Wong SC et al.. Outcomes with the polymer-based paclitaxel-eluting TAXUS stent in patients with diabetes mellitus: the TAXUS-IV trial. J Am Coll Cardiol. 2005; 45(8):1172-1179.
• [33]Jain AK, Lotan C, Meredith IT, Feres F, Zambahari R, Sinha N et al.. Twelve- month outcomes in patients with diabetes implanted with a zotarolimus-eluting stent: results from the E-Five Registry. Heart. 2010; 96(11):848-853.
• [34]Kereiakes DJ, Cutlip DE, Applegate RJ, Wang J, Yaqub M, Sood P et al.. Outcomes in diabetic and nondiabetic patients treated with everolimus- or paclitaxel-eluting stents: results from the SPIRIT IV clinical trial (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System). J Am Coll Cardiol. 2010; 56(25):2084-2089.
• [35]Kuchulakanti PK, Chu WW, Torguson R, Clavijo L, Wolfram R, Mishra S et al.. Sirolimus-eluting stents versus Paclitaxel-eluting stents in the treatment of coronary artery disease in patientswith diabetes mellitus. Am J Cardiol. 2006; 98(2):187-192.
• [36]Mehran R, Dangas GD, Kobayashi Y, Lansky AJ, Mintz GS, Aymong ED et al.. Short- and long-term results after multivessel stenting in diabetic patients. J Am Coll Cardiol. 2004; 43(8):1348-1354.
• [37]Mulukutla SR, Vlachos HA, Marroquin OC, Selzer F, Holper EM, Abbott JD et al.. Impact of drug-eluting stents among insulin-treated diabetic patients: a report from the National Heart, Lung, and Blood Institute Dynamic Registry. JACC Cardiovasc Interv. 2008; 1(2):139-147.
• [38]Nakamura M, Yokoi H, Hamazaki Y, Watarai M, Kijima M, Mitsudo K. Cypher J-PMS Investigators. Impact of insulin-treated diabetes and hemodialysis on longterm clinical outcomes following sirolimus-elutingstent deployment. Insights from a sub-study of the Cypher Stent Japan Post-Marketing Surveillance (Cypher J-PMS) Registry. Circ J. 2010; 74(12):2592-2597.
• [39]Schofer J, Schlüter M, Rau T, Hammer F, Haag N, Mathey DG. Influence of treatment modality on angiographic outcome after coronary stenting in diabetic patients: a controlled study. J Am Coll Cardiol. 2000; 35(6):1554-1559.
• [40]Stein B, Weintraub WS, Gebhart SP, Cohen-Bernstein CL, Grosswald R, Liberman HA et al.. Influence of diabetes mellitus on early and late outcome after percutaneous transluminal coronary angioplasty. Circulation. 1995; 91(4):979-989.
• [41]Stone GW, Kedhi E, Kereiakes DJ, Parise H, Fahy M, Serruys PW, Smits PC. Differential clinical responses to everolimus-eluting and Paclitaxel-eluting coronary stents in patients with and without diabetes mellitus. Circulation. 2011; 124(8):893-900.
• [42]Witzenbichler B, Mehran R, Guagliumi G, Dudek D, Huber K, Kornowski R et al.. Impact of diabetes mellitus on the safety and effectiveness of bivalirudin in patients with acute myocardialinfarction undergoing primary angioplasty: analysis from the HORIZONS-AMI (Harmonizing Outcomes with RevasculariZatiON and Stents in Acute Myocardial Infarction) trial. JACC Cardiovasc Interv. 2011; 4(7):760-768.
• [43]Kappetein AP, Head SJ, Morice M-C et al.. Treatment of complex coronary artery disease in patients with diabetes: 5-year results comparing outcomes of bypass surgery and percutaneous coronary intervention in the SYNTAX trial. Eur J Cardiothorac Surg. 2013; 43:1006-1013.